sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C. · 2016

Read sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. by Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5120370.txt.

Introduction

Marc Suárez-Calvet and a large team of co-authors tested a spinal fluid marker for Alzheimer's disease in EMBO Molecular Medicine in 2016. Suárez-Calvet leads with his first surname, as Spanish naming prints two. The marker is sTREM2, a fragment shed from a receptor on microglia, the brain's immune cells, whose faulty gene raises Alzheimer's risk.

Across several centers, spinal fluid sTREM2 was highest in patients whose mild memory problems stemmed from Alzheimer's, higher than in other disease stages and in controls. People with signs of non-Alzheimer pathology but normal thinking also showed raised levels. Higher sTREM2 tracked with tau markers of nerve damage. The pattern suggests microglia react early in the disease, and that sTREM2 could flag that early response.

Catalog record

CREATORSuárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5120370

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers By Marc Suárez‐Calvet, Gernot Kleinberger, Miguel Ángel Araque Caballero, Matthias Brendel, Axel Rominger, Daniel Alcolea, Juan Fortea, Alberto Lleó, Rafael Blesa, Juan Domingo Gispert, Raquel Sánchez‐Valle, Anna Antonell Published in: EMBO Molecular Medicine DOI: 10.15252/emmm.201506123 ABSTRACT Abstract TREM2 is an innate immune receptor expressed on the surface of microglia. Loss‐of‐function mutations of TREM2 are associated with increased risk of Alzheimer's disease (AD). TREM2 is a type‐1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (sTREM2), which can be measured in the cerebrospinal fluid (CSF). In this cross‐sectional multicenter study, we investigated whether CSF levels of sTREM2 are changed during the clinical course of AD, and in cognitively normal individuals with suspected non‐AD pathology (SNAP). CSF sTREM2 levels were higher in mild cognitive impairment due to AD than in all other AD groups and controls. SNAP individuals also had significantly increased CSF sTREM2 compared to controls. Moreover, increased CSF sTREM2 levels were associated with higher CSF total tau and phospho‐tau181P, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration. Keywords: Alzheimer's disease, biomarkers, microglia, neurodegeneration, TREM2 Subject Categories: Biomarkers & Diagnostic Imaging, Neuroscience INTRODUCTION Heterozygous missense mutations in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) have been recently described to significantly increase the risk of late onset Alzheimer's disease (AD) with an odds ratio similar to that of carrying an apolipoprotein E (APOE) ε4 allele (Guerreiro et al, 2013a; Jonsson et al, 2013). Heterozygous missense mutations in TREM2 also increase the risk for other neurodegenerative diseases (Borroni et al, 2013; Rayaprolu et al, 2013; Cuyvers et al, 2014), and homozygous loss‐of‐function mutations in TREM2 cause Nasu–Hakola disease (NHD) (Paloneva et al, 2002) and frontotemporal dementia (FTD)‐like syndrome (Guerreiro et al, 2013b), which are both early‐onset neurodegenerative diseases presenting as a frontal syndrome. Together, these findings indicate that TREM2 may be a common denominator in the pathogenesis of several different neurodegenerative diseases. TREM2 is a type‐1 transmembrane glycoprotein with an immunoglobulin‐like extracellular domain, one transmembrane domain and a short cytosolic tail (Klesney‐Tait et al, 2006). It belongs to the TREM family of innate immune receptors and is expressed in cells of the monocytic lineage (Bouchon et al, 2001; Schmid et al, 2002; Paloneva et al, 2003; Kiialainen et al, 2005). In the central nervous system (CNS), it is selectively expressed by microglia and involved in regulating phagocytosis and removal of apoptotic neurons as well as in the inhibition of microglia proinflammatory response (Takahashi et al, 2005; Klesney‐Tait et al, 2006; Hsieh et al, 2009; Wang et al, 2015). We have shown that loss‐of‐function of TREM2 impairs the phagocytic activity of microglial cells and reduces clearance of amyloid β‐peptide (Aβ; Kleinberger et al, 2014), suggesting that TREM2 may play an important role in the development of AD pathology and neurodegeneration during the course of the disease. TREM2 undergoes proteolytic processing, releasing its ectodomain into the extracellular space as a soluble variant (sTREM2) via shedding by ADAM proteases (Wunderlich et al, 2013; Kleinberger et al, 2014), and can be detected in human plasma and cerebrospinal fluid (CSF) (Piccio et al, 2008; Kleinberger et al, 2014). Piccio et al found that CSF sTREM2 levels were increased in multiple sclerosis and other neurological inflammatory diseases (Piccio et al, 2008). We described that sTREM2 was almost undetectable in the CSF and plasma of a FTD‐like patient carrying a homozygous TREM2 p.T66M mutation. This mutation leads to misfolding of the full‐length protein, which accumulates within the endoplasmic reticulum. Due to the lack of cell surface transport, shedding is dramatically reduced, which explains the absence of sTREM2 in patients with the homozygous TREM2 p.T66M mutation (Kleinberger et al, 2014). In contrast, we observed a slight decrease in CSF sTREM2 levels in AD dementia patients compared to elderly cognitively normal subjects (Kleinberger et al, 2014). While our manuscript was under consideration, we learned that two groups independently found that CSF sTREM2 was increased in AD patients (Heslegrave et al, 2016; Piccio et al, 2016). Taken together, these results suggest that CSF sTREM2 levels are altered not only in subjects with TREM2 mutations but also in sporadic cases of neurodegenerative diseases. In AD, amyloid plaques and neurofibrillary tangles, the major pathological hallmarks of the disease, develop decades before the onset of clinical symptoms (Morris et al, 1996; Braak & Braak, 1997; Hulette et al, 1998; Price & Morris, 1999). Increased microglial activation and neuroinflammation frequently accompanies the early development of Aβ and tau pathology (Mosher & Wyss‐Coray, 2014; Streit et al, 2014; Heneka et al, 2015; Tanzi, 2015). Since TREM2 is a key protein involved in the activation of microglia, the question arises whether TREM2 levels are pathologically altered in the early course of AD. If so, CSF sTREM2 would be an attractive biomarker candidate for tracking of the disease and as a potential outcome parameter for future clinical trials focusing on TREM2 and neuroinflammation. However, it is not known whether CSF sTREM2 levels change during the different stages of AD, a question that we addressed in the current study. The main aim of this cross‐sectional multicenter study was to determine whether the levels of CSF sTREM2 change across the continuum of AD. We tested CSF TREM2 in subjects with preclinical AD, mild cognitive impairment (MCI) due to AD (MCI‐AD), and AD dementia and controls, defined by clinical and CSF biomarker criteria as recommended by the National Institute on Aging‐Alzheimer's Association (NIA‐AA) criteria (Albert et al, 2011; McKhann et al, 2011; Sperling et al, 2011). We also tested whether CSF sTREM2 levels are associated with the core AD CSF biomarkers Aβ1–42, total tau (T‐tau) and tau phosphorylated at threonine 181 (P‐tau181P) (Blennow et al, 2010). As a secondary aim, we investigated whether CSF sTREM2 levels are altered in cognitively normal subjects with suspected non‐AD pathology (SNAP) and MCI subjects without CSF biomarker evidence of AD pathology (MCI‐noAD). SNAP is a recently defined diagnostic category that comprises those individuals with abnormal neurodegeneration biomarkers (T‐tau and P‐tau181P) but without evidence of underlying amyloidosis (Jack et al, 2012) and might thus represent neurodegenerative diseases different from AD. RESULTS Study population The current study included 150 controls and 63 preclinical AD, 111 MCI‐AD as well as 200 AD dementia subjects (Table 1). The diagnostic criteria of each group were defined according to the NIA‐AA criteria, which uses a combination of clinical diagnosis and the CSF biomarker profile including Aβ1–42, T‐tau, and P‐tau181P (Albert et al, 2011; McKhann et al, 2011; Sperling et al, 2011). Decreased Aβ1–42 was a requisite for preclinical AD, and the combination of decreased Aβ1–42 and increased T‐tau and/or P‐tau181P for MCI‐AD and AD dementia. The control group consisted of asymptomatic cognitively normal individuals with all three AD CSF core biomarkers within the normal range. The diagnostic criteria are described in more detail in the methods section. The cutoff values to define abnormal CSF values

Read the complete text